Equity Details
Price & Market Data
Price: $2.87
Daily Change: -$0.104 / 3.63%
Daily Range: $2.85 - $3.09
Market Cap: $68,526,744
Daily Volume: 122,566
Performance Metrics
1 Week: -5.86%
1 Month: 58.79%
3 Months: -32.32%
6 Months: -52.93%
1 Year: -72.34%
YTD: -52.78%
About Actuate Therapeutics, Inc. Common stock (ACTU)
Financial summary for Actuate Therapeutics, Inc. Common stock (ACTU). Price: 2.87, daily change: -$0.104 / 3.63%. Market cap: 68,526,744. Performance for all periods at a glance.
Company Details
Employees: 12
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as neuroblastoma and pediatric leukemias. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. Actuate Therapeutics, Inc. was incorporated in 2015 and is headquartered in Fort Worth, Texas.